Amgen
AMGN
$432.49
-0.35%
Amgen is one of the world's largest independent biotechnology companies, developing and commercializing human therapeutics across oncology, inflammation, bone health, cardiovascular disease, and rare disease, with a portfolio spanning flagship brands such as Repatha, Prolia, Evenity, Otezla, Enbrel, and Tepezza (acquired via the 2023 Horizon deal) alongside a growing biosimilar franchise. It is a mature, cash-generative large-cap with an entrenched position in biologics manufacturing and a legacy franchise facing biosimilar erosion, positioning it as a defensive, dividend-paying compounder rather than a high-growth disruptor. The current investor narrative centers on the MariTide obesity program, where once-monthly dosing could carve a differentiated niche against Eli Lilly and Novo Nordisk, and on whether the Horizon rare-disease portfolio plus new oncology launches (Imdelltra, Blincyto) can offset erosion in legacy products. Sentiment has been complicated by regulatory overhangs, including partner-led safety scrutiny of Tavneos and the broader threat of drug tariffs, while the stock's strong 2026 run reflects improving revenue growth and margin recovery rather than a single binary catalyst.…
AMGN
Amgen
$432.49
Related headlines
Investment Opinion: Should I buy AMGN Today?
The synthesized recommendation is Hold. While Amgen boasts strong fundamentals—9.68% revenue growth, expanding margins, and a 17.65x forward PE—the stock's 46.21% one-year rally has pushed it above the analyst average target of $394.98 (implying 8.7% downside), and the consensus rating is a cautious 'hold' with a mean of 2.65. The core thesis is that the market has already priced in much of the good news, and investors should wait for a better entry point or clearer catalysts.
Supporting evidence includes the forward PE of 17.65x, which is reasonable for a large-cap pharma but not deeply discounted; the PEG ratio of 0.259 suggests undervaluation relative to growth, yet the trailing PE of 22.84x sits mid-range historically. Revenue growth of 9.68% YoY and gross margin expansion to 72.04% are positives, and free cash flow of $10.175 billion supports the 2.91% dividend yield. However, the 8.7% downside to the average target and the wide target range ($225-$500) signal uncertainty. The stock's technical momentum is strong, but it is overextended near resistance at $447.03.
Key risks that could invalidate the thesis include accelerated legacy erosion, MariTide disappointment, and regulatory/tariff headwinds. The rating would upgrade to Buy if the stock pulls back to the $375-$390 support zone (aligning with the analyst average target) or if MariTide data exceeds expectations. It would downgrade to Sell if revenue growth decelerates below 5% or if margins contract. Relative to history and peers, the stock appears fairly valued to slightly overvalued after its run-up, with limited margin of safety.
Sign up to view all
AMGN 12-Month Price Forecast
Amgen presents a balanced risk/reward profile: strong fundamentals and momentum are offset by a cautious analyst consensus and stretched valuation after a 46% rally. The stock's low beta (0.407) and defensive characteristics make it suitable for income-oriented investors, but the lack of margin of safety suggests waiting for a pullback. The key driver will be MariTide's clinical and commercial success, which could significantly alter the growth trajectory. I would upgrade to bullish if the stock retests the $375-$390 support zone or if MariTide data exceeds expectations; I would downgrade to bearish if revenue growth decelerates below 5% or if margins contract sharply.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Amgen's 12-month outlook, with a consensus price target around $394.98 and implied upside of -8.7% versus the current price.
Average Target
$394.98
0 analysts
Implied Upside
-8.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$225 - $500
Analyst target range
Coverage is broad, with 29 analysts, but the consensus is cautious: the recommendation is "hold" with a mean rating of 2.65 (where 1 is strong buy and 5 is strong sell), and the average target price of $394.98 actually implies roughly 8.7% downside from the current $432.49 — a notable disconnect given the stock's 46.21% one-year rally. This suggests analysts have been slow to revise targets upward and the stock has run ahead of published price objectives, a pattern often resolved either by target upgrades or by price consolidation. The consensus leans neutral-to-cautious rather than bullish, with the recent institutional ratings flow showing more downgrades than upgrades: HSBC cut to Hold from Buy (Sept 10), BMO cut to Market Perform from Outperform (Sept 8), while Scotiabank maintained Sector Outperform (Sept 29) and Piper Sandler and Argus reiterated Overweight/Buy. The target range is extremely wide — from a low of $225.00 to a high of $500.00, a spread of more than 2x — signaling high uncertainty about the MariTide obesity opportunity and the durability of legacy franchise erosion. The $500 high target likely assumes successful MariTide commercialization, sustained high-single-digit revenue growth, and multiple expansion toward premium biotech peers, while the $225 low target prices in severe biosimilar erosion, MariTide disappointment, and margin compression from tariff or pricing pressure. The wide dispersion, combined with a "hold" consensus below the current price, argues for caution on chasing the stock at these levels despite its strong technical momentum; the estimated 2026 EPS average of $29.63 and revenue average of $45.25 billion provide the fundamental anchor, and upside likely requires either analyst target revisions or a positive MariTide data catalyst.
Drowning in data?
Find the real signal!
Bulls vs Bears: AMGN Investment Factors
The bull case rests on revenue re-acceleration (9.68% YoY), margin expansion (gross margin up to 72.04%), and an attractive forward PE of 17.65x, supported by strong technical momentum and the optionality of MariTide. However, the bear case is equally compelling: analyst consensus is a 'hold' with an average target 8.7% below the current price, leverage is high at 6.31x debt-to-equity, and legacy erosion plus regulatory risks loom. Currently, the bear evidence appears slightly stronger given the disconnect between the stock's 46% one-year rally and cautious analyst targets, suggesting the stock has run ahead of fundamentals. The single most important tension is whether the growth from new products and MariTide can sustainably offset legacy erosion and justify the premium valuation—resolution of this debate will determine the stock's direction.
Bullish
- Revenue re-acceleration to 9.68% YoY: Q2 2026 revenue of $10.054 billion grew 9.68% year-over-year versus $9.167 billion in Q2 2025, and the sequential progression from $8.618 billion in Q1 2026 shows strong momentum. This suggests new products like Tezspire ($486 million), Blincyto ($472 million), and Imdelltra ($288 million) are successfully offsetting legacy erosion.
- Margin expansion and profitability: Gross margin expanded from 67.15% in Q2 2025 to 72.04% in Q2 2026, while operating margin reached 34.95%, up sharply from 28.84% a year earlier. Net income of $2.375 billion represents a 23.62% net margin, demonstrating improving operational efficiency.
- Attractive forward valuation: The stock trades at 17.65x forward earnings, a 22.7% discount to its trailing PE of 22.84x, implying expected EPS growth. The PEG ratio of 0.259 suggests the stock is inexpensive relative to its growth rate, and the 2.91% dividend yield offers income support.
- Strong technical momentum and relative strength: AMGN is up 46.21% over the past year and 32.00% year-to-date, outpacing the S&P 500's 15.53% and 11.93% gains. Relative strength is positive across all windows (+30.68% vs. SPY over one year), and the stock sits at 90.9% of its 52-week range, signaling market leadership.
Bearish
- Analyst consensus hold with downside to target: The consensus recommendation is 'hold' with a mean rating of 2.65, and the average target price of $394.98 implies 8.7% downside from the current $432.49. Recent downgrades from HSBC and BMO suggest analysts are cautious about the stock's run-up.
- High leverage from Horizon acquisition: Debt-to-equity stands at 6.31x with total debt to capitalization of 83.06%, a legacy of the Horizon deal. While interest coverage of 5.22x is adequate, the heavy debt burden limits financial flexibility and leaves little room for aggressive deleveraging given the 66.45% dividend payout ratio.
- Legacy franchise erosion risk: Key products like Enbrel ($580 million) and Otezla ($491 million) face biosimilar and generic competition. The 9.68% growth rate may not be sustainable if erosion accelerates, and the wide analyst target range ($225-$500) reflects uncertainty about the durability of the growth offset.
- Regulatory and legal overhangs: Partner-led safety scrutiny of Tavneos and the threat of 100% drug tariffs pose risks. The September 8 gap down from $437.23 to $393.17 coincided with market-wide geopolitical tensions, highlighting sensitivity to external shocks despite low beta.
AMGN Technical Analysis
Amgen is in a sustained, powerful uptrend, with the stock up 46.21% over the past year and 32.00% year-to-date, dramatically outpacing the S&P 500's 15.53% and 11.93% respective gains. At $432.49, the stock sits at roughly 90.9% of its 52-week range (low $288.00, high $447.03), just below its highs — a positioning that signals strong momentum but also raises the risk of overextension and profit-taking near resistance. The 180-day price series confirms a stair-step advance from the ~$330s in April-May to the $430s by October, with the only meaningful interruption being the sharp September 8 gap down from $437.23 to $393.17. Short-term momentum is accelerating: the stock is up 14.92% over the past month and 18.07% over three months, with the 1-month gain actually exceeding the 3-month gain, indicating re-acceleration rather than deceleration. Relative strength is decisively positive across every window — +13.70% versus SPY over one month, +15.38% over three months, and +30.68% over one year — confirming Amgen as a market leader rather than a beta-driven beneficiary. The September drawdown to $375.65 was fully recovered within weeks, and the October push back above $430 suggests buyers are defending the trend. Key support sits at the 52-week low of $288.00, with intermediate support around the September swing low of $375.65 and the $390-$400 shelf; resistance is the 52-week high of $447.03, with the September 3 close of $444.12 marking the immediate ceiling. A breakout above $447 would confirm the uptrend's continuation and likely invite momentum buyers, while a breakdown below $375 would break the pattern of higher lows and signal a trend reversal. Volatility is unusually low for a single-name pharma: beta of 0.407 means the stock moves roughly 40% as much as the market, and the max drawdown of -16.57% over the period is modest, supporting larger position sizing for risk-managed investors but also implying that the recent rally is driven by idiosyncratic, stock-specific flows rather than broad market beta.
Beta
0.41
0.41x market volatility
Max Drawdown
-16.6%
Largest decline past year
52-Week Range
$288-$447
Price range past year
Annual Return
+46.2%
Cumulative gain past year
| Period | AMGN Return | S&P 500 |
|---|---|---|
| 1m | +14.9% | +0.2% |
| 3m | +18.1% | +2.9% |
| 6m | +21.7% | +8.4% |
| 1y | +46.2% | +14.9% |
| ytd | +32.0% | +11.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
AMGN Fundamental Analysis
Revenue is re-accelerating, with Q2 2026 revenue of $10.054 billion growing 9.68% year-over-year versus $9.167 billion in Q2 2025, and the sequential progression from $8.618 billion in Q1 2026 to $10.054 billion in Q2 shows strong momentum. The trailing four quarters total roughly $37.7 billion ($8.618B + $10.054B + $9.896B + $9.557B), and the product mix reveals a well-diversified base: Repatha at $953 million, Prolia at $759 million, Evenity at $714 million, Enbrel at $580 million, Tepezza at $576 million, and Otezla at $491 million, with newer growth drivers like Tezspire ($486 million), Blincyto ($472 million), and Imdelltra ($288 million) scaling. The key fundamental debate is whether these growth products can outrun biosimilar and generic erosion in legacy franchises, and the 9.68% growth rate suggests they currently are. Profitability is robust and improving: Q2 2026 net income was $2.375 billion on a 23.62% net margin, gross margin was 72.04%, and operating margin reached 34.95%, up sharply from the 28.84% operating margin in Q2 2025 and the depressed 14.46% in Q1 2025. The margin trajectory has been volatile due to acquisition-related amortization and one-time items (note the -$2.428 billion in other income/expenses in Q4 2025 and -$1.076 billion in Q2 2025), but the underlying trend is clearly upward, with gross margin expanding from 67.15% in Q2 2025 to 72.04% in Q2 2026. Balance sheet leverage is the notable risk: debt-to-equity stands at 6.31x (total debt to capitalization of 83.06%), a legacy of the Horizon acquisition, though interest coverage of 5.22x and a current ratio of 1.14 indicate the company can service its obligations. Cash generation remains solid, with TTM free cash flow of $10.175 billion, Q2 2026 operating cash flow of $4.002 billion against capex of $513 million, and cash of $13.989 billion at quarter-end; however, dividends of $1.362 billion per quarter consume a meaningful share of FCF, and the 2.91% dividend yield with a 66.45% payout ratio leaves limited room for aggressive deleveraging without continued EBITDA growth.
Quarterly Revenue
$10.1B
2026-06
Revenue YoY Growth
+9.7%
YoY Comparison
Gross Margin
72.0%
Latest Quarter
Free Cash Flow
$10.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is AMGN Overvalued?
Because Amgen is solidly profitable (Q2 2026 net income of $2.375 billion), the PE ratio is the appropriate primary metric. The stock trades at 22.84x trailing earnings but only 17.65x forward earnings — a 22.7% compression that implies the market expects meaningful EPS growth, consistent with the consensus 2026 EPS estimate of $29.63 versus the current run-rate. The forward PE of 17.65x is reasonable for a large-cap pharma with high-single-digit revenue growth and expanding margins, and the PEG ratio of 0.259 suggests the stock is inexpensive relative to its growth rate. Against the broader Drug Manufacturers - General industry, Amgen's 22.84x trailing PE and 4.79x PS sit at a premium to slower-growing peers but at a discount to high-growth biotech; the 7.30x EV/Sales and 13.11x EV/EBITDA are moderate for a company with 70.80% gross margins and 29.06% operating margins. The 20.34x price-to-book is elevated, but this is an artifact of the Horizon deal's goodwill and the company's thin book equity (ROE of 89.06% reflects a heavily levered capital structure rather than exceptional returns on assets, with ROA at just 8.67%). Historically, Amgen's PE has ranged widely — from 11.80x in Q3 2025 to 55.69x in Q4 2024 and 33.13x in Q4 2025 — so the current 22.84x sits in the middle of its own multi-year band, neither stretched nor cheap. The PS ratio of 4.79x compares favorably to historical levels of 15.5x-22.0x in 2025-2026 (though those figures appear to use different share-count conventions), and the dividend yield of 2.91% is well above the ~0.7% levels seen in the historical ratio data, suggesting the stock has become more income-attractive as the price has risen alongside the payout. Net-net, valuation is supportive but not deeply discounted: the market is pricing in continued execution on MariTide and margin expansion, leaving limited cushion if growth disappoints.
PE
22.8x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 11x~33x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.1x
Enterprise Value Multiple
Investment Risk Disclosure
Amgen's financial risk is dominated by its elevated leverage, with a debt-to-equity ratio of 6.31x and total debt to capitalization of 83.06%, largely stemming from the $27.8 billion Horizon acquisition. While interest coverage of 5.22x and a current ratio of 1.14 indicate the company can service its obligations, the heavy debt load restricts financial flexibility. Additionally, the dividend payout ratio of 66.45% consumes a significant portion of free cash flow ($10.175 billion TTM), leaving limited room for aggressive deleveraging or reinvestment without continued EBITDA growth. Margin volatility due to acquisition-related amortization and one-time items (e.g., -$2.428 billion in other expenses in Q4 2025) adds earnings uncertainty.
Market and competitive risks include valuation compression if growth disappoints, given the stock's premium to slower-growing peers and its mid-range historical PE of 22.84x. The low beta of 0.407 suggests the stock is less sensitive to market swings, but sector rotation away from defensive pharma could pressure shares. Competitive threats are intensifying: Eli Lilly and Novo Nordisk dominate obesity, and Pfizer's berobenatide could enter the space, challenging MariTide's differentiation. Regulatory headwinds, such as the proposed 100% drug tariffs and safety scrutiny on Tavneos, could disrupt operations and sentiment. Recent news highlights these threats, including J&J's sales miss amid biosimilar competition and geopolitical tensions causing market-wide selloffs.
In a worst-case scenario, a combination of MariTide clinical failure, accelerated legacy erosion, and margin compression from tariffs could drive the stock toward its 52-week low of $288.00, representing a 33.4% decline from the current $432.49. The analyst low target of $225.00 implies an even steeper 48.0% downside, reflecting severe pessimism. A more realistic adverse scenario might see the stock retest the September swing low of $375.65 (-13.1%) or the $390-$400 support shelf. Given the max drawdown of -16.57% over the past 180 days, a 20-30% correction is plausible if growth stalls, wiping out a significant portion of recent gains.
FAQ
The most severe risk is financial leverage: debt-to-equity of 6.31x and a 66.45% dividend payout ratio limit flexibility, especially if cash flow declines. Competitive risk is high, with legacy products like Enbrel and Otezla facing biosimilar erosion, and MariTide competing against entrenched obesity drugs from Eli Lilly and Novo Nordisk. Regulatory risks include potential 100% drug tariffs and safety scrutiny on Tavneos, which could disrupt sales and reputation. Macro risk is relatively low given the 0.407 beta, but sector rotation away from defensive pharma could pressure the stock. Company-specific risk centers on clinical trial outcomes for MariTide; failure could trigger a sharp selloff toward the $288 low.
Our 12-month forecast presents three scenarios: a bull case (25% probability) targeting $480-$500, driven by MariTide success and margin expansion; a base case (55% probability) targeting $380-$420, assuming steady execution and consolidation around the analyst average of $394.98; and a bear case (20% probability) targeting $288-$340, reflecting MariTide disappointment and accelerated erosion. The base case is most likely, as it aligns with consensus estimates and the current valuation. The key assumption is that revenue growth remains in the high-single digits and margins hold, with no major negative surprises. Investors should monitor quarterly results and MariTide updates for confirmation.
AMGN appears fairly valued to slightly overvalued after its strong run. The trailing PE of 22.84x is in the middle of its historical range (11.80x to 55.69x), while the forward PE of 17.65x suggests the market expects EPS growth. The PEG ratio of 0.259 indicates undervaluation relative to growth, but the 20.34x price-to-book is elevated due to acquisition goodwill. Compared to peers, the 4.79x PS and 13.11x EV/EBITDA are moderate for a large-cap pharma with high margins. The market is pricing in continued execution on MariTide and margin expansion, leaving little room for disappointment. A pullback to the $375-$390 range would offer a more attractive entry point.
From a risk/reward perspective, AMGN is a moderate buy only on pullbacks. The stock trades at $432.49, above the analyst average target of $394.98 (8.7% downside), and the consensus rating is 'hold'. While fundamentals are solid—9.68% revenue growth, 72.04% gross margin, and a 17.65x forward PE—the recent 46% rally has likely priced in much of the near-term optimism. The biggest downside risk is a retest of the 52-week low of $288 (-33%), but the low beta (0.407) and dividend yield (2.91%) provide some defense. For long-term income investors, dollar-cost averaging into weakness is prudent; for short-term traders, waiting for a breakout above $447 or a pullback to $375-$390 is advisable.
AMGN is best suited for long-term investment, given its defensive characteristics, low beta (0.407), and reliable dividend (2.91% yield). The company is a mature cash generator with a stable revenue base, making it appropriate for income-focused portfolios. Short-term trading is less attractive due to the stock's overextended technicals and the 8.7% downside to the analyst average target. Earnings visibility is moderate, with the next catalyst likely in Q3 2026 earnings. A minimum holding period of 2-3 years is recommended to ride out volatility and benefit from potential MariTide commercialization and pipeline growth.
